PaxMedica, Inc. Common Stock
PXMD
PXMD was delisted on the 1st of May, 2024.
8 hedge funds and large institutions have $176K invested in PaxMedica, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 3 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
83% more capital invested
Capital invested by funds: $96.1K → $176K (+$80K)
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
33% more funds holding
Funds holding: 6 → 8 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$57.2K |
| 2 |
State Street
Boston,
Massachusetts
|
+$46K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$30.6K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$7.54K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$2.11K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$43K |
| 2 |
VF
Virtu Financial
New York
|
-$8.4K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$59 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $67.8K | +$57.2K | +1,600 | +438% |
|
|
2
State Street
Boston,
Massachusetts
| $44.5K | +$46K | +1,288 | New |
|
|
3
Bank of America
Charlotte,
North Carolina
| $29.5K | +$30.6K | +856 | New |
|
|
VF
4
Virtu Financial
New York
| $21K | -$8.4K | -235 | -28% |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $11K | +$7.54K | +211 | +192% |
|
|
6
Osaic Holdings
Scottsdale,
Arizona
| $2K | +$2.11K | +59 | New |
|
7
Barclays
London,
United Kingdom
| $204 | +$214 | +6 | New |
|
8
Wells Fargo
San Francisco,
California
| $45 | +$36 | +1 | New |
|
|
9
Jane Street
New York
| – | -$43K | -1,060 | Closed |
|
|
10
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$59 | -882 | Closed |
|
PXMD Hedge Fund Activity: Q4 2022 in Review
8 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in PaxMedica, Inc. Common Stock (PXMD) for Q4 2022, worth a combined $176K — up 83% from $96.1K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new PXMD positions and 3 closed out — a net gain of 2 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was UBS Group, adding an estimated $57.2K. The largest seller was Jane Street, exiting entirely with an estimated $43K sold.
- 8 institutional investors held PaxMedica, Inc. Common Stock (PXMD) as of Q4 2022, up from 6 in Q3 2022.
- Funds reported $176K of PaxMedica, Inc. Common Stock stock for Q4 2022, up 83% quarter-over-quarter.
- 5 funds opened new PaxMedica, Inc. Common Stock positions in Q4 2022 and 3 closed out, a net change of +2 holders.
- The largest PaxMedica, Inc. Common Stock buyer in Q4 2022 was UBS Group, an estimated $57.2K added.
- The largest PaxMedica, Inc. Common Stock seller in Q4 2022 was Jane Street, an estimated $43K sold.
Based on aggregated 13F filings for Q4 2022.